因素方法:凝血治疗优化和建议 (FACTOR)
Sara Leidy1, Zahra Mahmoudjafari1
1From The University of Kansas Cancer Center, Westwood, Kansas.
Journal of the advanced practitioner in oncology
|December 5, 2025
概括
管理血液因子产品,如因子VIIa,VIII,IX和·维勒布兰德因子,需要仔细制定配方和基于证据的指导方针. 这种方法最大限度地提高了患者的治疗结果,并最大限度地降低了治疗出血障碍的风险.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 健康管理健康管理
背景情况:
- 外源性血液因子 (例如,因子VIIa,VIII,IX,·维勒布兰德因子) 对于治疗出血障碍至关重要.
- 这些疗法存在重大风险和高成本.
- 优化它们的使用对于患者安全和资源管理至关重要.
研究的目的:
- 概述血液因子产品表单的开发过程.
- 详细介绍这些高风险,高成本药物的管理策略.
- 强调学术医疗中心的跨专业方法.
主要方法:
- 审查关于表单管理和基于证据的指南的当前文献.
- 描述为血液因子产品制定机构指导方针的关键步骤.
- 在表单决策中考虑跨专业合作.
主要成果:
- 对配方开发的结构化方法可以提高血液因子的安全和成本效益的使用.
- 基于证据的指导方针对于标准化治疗和尽量减少不良事件至关重要.
- 专业间的协作确保对产品的选择和使用进行全面的评估.
结论:
- 开发和管理血液因子产品配方对于学术医疗中心至关重要.
- 基于证据的跨专业策略最大限度地提高了患者的结果,并最大限度地降低了与这些疗法相关的风险.
- 有效的配方管理有助于临床疗效和经济可持续性.
更多相关视频
09:38A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
14.3K
13:08Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
19.3K
相关概念视频
Venous Thrombosis III: Interprofessional Care
265
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
265
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Coagulation
9.5K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.5K
Coagulation
1.2K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.2K
Clot Retraction and Fibrinolysis
8.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.3K
